Intrinsic resistance of Escherichia coli to mureidomycin A and C due to expression of the multidrug efflux system AcrAB-TolC: Comparison with the efflux systems of mureidomycin-susceptible Pseudomonas aeruginosa

Journal of Infection and Chemotherapy

Volumn 9, Issue 1, 2003, Pages 101-103

  Gotoh, Naomasa ^a,b   Murata, Takeshi ^a   Ozaki, Toru ^a   Kimura, Tadashi ^a   Kondo, Akiko ^a   Nishino, Takeshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

AcrAB TolC; MexAB OprM; MexCD OprJ; MexXY OprM; Mureidomycins

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; MUREIDOMYCIN A; MUREIDOMYCIN C; PROTEIN ACRABTOLC; PROTEIN MEXABOPRM; PROTEIN MEXCDOPRJ; PROTEIN MEXXYOPRM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SPECIES DIFFERENCE;

EID: 0037367365     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-002-0205-2     Document Type: Article

References (19)

1. Isono F, Kodama K, Inukai M. Susceptibility of Pseudomonas species to the novel antibiotic mureidomycins. Antimicrob Agents Chemother 1992;36:1024-7.
2. Brandish PE, Kimura K, Inukai M, Southgate R, Lonsdale JT, Bugg TDH. Modes of action of tunicamycin, Liposidomycin A, and mureidomycin A: inhibition of phosphor-N-acetylmuramyl-pentapeptide translocase from Escherichia coli. Antimicrob Agents Chemother 1996;40:1640-4.
3. Isono F, Inukai M. Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis. Antimicrob Agents Chemother 1991;35: 234-6.
4. Ma D, Cook DN, Hearst JE, Nikaido H. Efflux pumps and drug resistance in gram-negative bacteria. Trends Microbiol 1994;2:489-93.
5. Fralick JA. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol 1996;178: 5803-5.
6. Gotoh N, Itoh N, Tsujimoto H, Yamagishi J, Oyamada Y, Nishino T. Isolation of OprM-deficient mutants of Pseudomonas aeruginosa by transposon insertion mutagenesis: evidence of involvement in multiple antibiotic resistance. FEMS Microbiol Lett 1994;122:267-74.
7. Poole K, Krebs KK, McNally C, Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993;175:7363-72.
8. Hiraga S, Niki H, Ogura T, Ichinose C, Mori H. Ezaki B, Jaffe A. Chromosome portioning in Escherichia coli: novel mutants producing anucleate cells. J Bacteriol 1989;171:1496-505.
9. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:3322-7.
10. Washington JA, Barry AL. Dilution test procedures. In: Lennette EH, Spaulding EH, Traunt JT, editors. Manual of clinical microbiology. 2nd Ed. Washington, DC: American Society for Microbiology; 1974. p. 410-7.
11. Lynch MJ, Drusano GL, Mobley HLT. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1987;31:1892-6.
12. Breithaupt H. The new antibiotics. Nat Biotech 1999;17:1165-9.
13. Payne DJ, Warren PV, Holmes DJ, Ji Y, Lonsdale JT. Bacterial fatty-acid biosynthesis: a genome-driven target for antibacterial drug discovery. Drug Discovery Today 2001;6:537-44.
14. Yuan Z, Trias J, White RJ. Deformylase as a novel antibacterial target. Drug Discovery Today 2001;6:954-61.
15. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:2242-6.
16. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis. Antimicrob Agents Chemother 2000;44:710-2.
17. Pai H, Kim J-W, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001;45:480-4.
18. Lomovskaya O, Watkins WJ. Efflux pumps: their role in antibacterial drug discovery. Curr Med Chem 2001;8:1699-711.
19. Lomovskaya O, Watkins WJ. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001;3:225-36.